Letro-Cell

Letrozole, the active ingredient in Letro-Cell, is a aromatase inhibitor presented as an oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that fuel tumor growth.

GNH USA supplies Letro-Cell as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letro-Cell, an aromatase inhibitor, is used in the management of estrogen‑driven breast cancer. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor progression by decreasing peripheral estrogen synthesis. - Adjuvant therapy after surgery for early‑stage disease: lowers recurrence risk when combined with other oncologic treatments. - Metastatic breast cancer in postmenopausal patients: provides disease control by limiting estrogen‑mediated tumor growth.

Letro-Cell may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Nausea: mild to moderate upset stomach. - Fatigue: reduced energy levels. - Headache: mild to moderate intensity. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Osteoporosis or bone fracture: decreased bone mineral density. - Severe liver injury: elevated transaminases or hepatitis. - Cardiovascular events: thromboembolism or myocardial infarction. - Severe allergic reaction: rash, angioedema, or anaphylaxis.

Before initiating Letro-Cell, clinicians should evaluate several safety considerations. - Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation. - Assess liver function: obtain hepatic enzyme tests prior to and during therapy. - Contraindicated in pregnancy: letrozole is Category X and must not be used by pregnant individuals. - Evaluate cardiovascular risk: review history of thromboembolic disease or myocardial infarction. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letro-Cell can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract letrozole’s estrogen‑lowering effect. - Strong CYP2A6 inducers (e.g., rifampin): can markedly reduce letrozole plasma concentrations. - Tamoxifen: antagonistic action may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin: increased risk of bleeding; monitor INR. - CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole exposure, watch for toxicity. - Diuretics: monitor electrolytes and renal function during combined use.